Data source | N | Study label (n = 46)a |
---|---|---|
(1) Individual-level epidemiological data | 8 | BODE3 models – Boyd (2020) [54], Deverall (2018) [62], Pega (2016) [82], Wilson (2017) [92]; Eldridge (2005) [63]; Ippoliti (2018) [72]; OMAS (2008) [81]; Smith (2016) [88] |
(2) Published epidemiological data or expert/author opinion | 25 | Agartioglu (2020) [50]; Carande-Kulis (2015) [55]; CSP (2016) [56]; Church (2011) [57]; Church (2012) [58]; Farag (2015) [64]; Franklin (2019) [65]; Frick (2010) [66]; Hiligsmann (2014) [68]; Hirst (2016) [69]; Honkanen (2006) [70]; Howland (2015) [71]; Lee (2013) [74]; Ling (2008) [75]; Miller (2011) [77]; Mori (2017) [78]; Moriarty (2019) [79]; Nshimyumukiza (2013) [80]; Poole (2014) [83]; Poole (2015) [84]; RCN (2005) [34]; Tannenbaum (2015) [89]; Turner (2020) [90]; Wu (2010) [93]; Zarca (2014) [94] |
(3) Internal intervention studyb evidence | 9 | Albert (2016) [51]; Alhambra-Borras (2019) [52]; Beard (2006) [53]; Comans (2009) [59]; Johansson (2008) [73]; McLean (2015) [76]; Sach (2007) [86]; Sach (2010) [87]; Velde (2008) [91] |
(4) Risk/rate from external RCT control group | 4 | Day (2009) [60]; Day (2010) [61]; Hektoen (2009) [67]; PHE (2018) [85] |